Guidance for manufacturers of cardiac implantable electronic devices and their leads. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Similar Posts
Government to align with European specifications on high risk in vitro diagnostic devices to reduce regulatory burden
The specifications will establish standards for high-risk diagnostic tests while creating consistency with European regulations
MHRA welcomes Professor Jonathan Benger CBE as new CEO of NICE
Professor Benger’s leadership comes at a pivotal time as the MHRA and NICE deepen collaboration
MHRA approves adrenaline nasal spray – the first needle-free emergency treatment for anaphylaxis in the UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, with different stated mg dose but similar bioavailability, will both be available on the market.
Looking to our future: reflections on the strategic choices ahead for the MHRA
As part of developing its new five-year strategy, the MHRA is publishing a series of blogs on the challenges and opportunities ahead. In the first instalment, Chief Executive Lawrence Tallon reflects on the changing healthcare landscape, the regulator’s role, and the priorities shaping the agency’s future direction.
Research: Digital mental health technology: user and public perspectives on identifying and reporting harms
A research report on attitudes regarding identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme.